Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
about
Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmiasA systematic review of the cardiotoxicity of methadoneCurrent and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.Pharmacological strategies for detoxification.Opioid dependence treatment: options in pharmacotherapy.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reportsBlood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparationStereoselective Inhibition of the hERG1 Potassium Channel.Combating opiate dependence: a comparison among the available pharmacological options.Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trialRole of buprenorphine in the management of heroin addiction.Opioid maintenance: a comparative review of pharmacological strategies.The Impact of Opioids on Cardiac Electrophysiology.Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.Methadone-Associated QTc Prolongation: A Case Report and Review of the Literature.Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem.A community-based evaluation of sudden death associated with therapeutic levels of methadone.Electrocardiographic findings associated with cocaine use in humans: a systematic review.QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.A comparison of the risk of QT prolongation among SSRIs.Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings.Opioid addiction agonist therapy and the QT prolongation phenomenon: state of the science and evolving research questions.Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon.Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.[Brazilian guideline for the treatment of patients with opioids dependence syndrome].Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes.QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.Analgesics and Antipyretics
P2860
Q24634668-9BD74E03-14B9-4C93-8060-9B4CEEE5C8ACQ26766513-9DB0675E-82B5-49B0-A59F-936215366802Q27692554-CC59F17C-0188-4B5B-AA26-71EA2EF18512Q33582092-99926DC3-189B-4C5C-99F1-F21218933543Q33868638-A68B2ABB-7239-4884-A44D-DD0E91ACF4D7Q33870389-91DCC1C9-E7AA-4483-A58B-FE0770A56655Q34016220-5C8328A2-6182-430F-AA8B-7444475E2945Q35098619-E2C75ECC-0889-4791-A9AA-F438895C2EC1Q35155243-07D5D47E-1E9D-4169-8415-48A1FE098F40Q35753371-6FF983E2-4830-4D9A-AFCC-711090BA343FQ35959993-34B8FFC6-7140-4CE0-802F-FED6D413BB73Q36376715-91222231-0850-481B-B7EB-44E0CA1E5D33Q36681297-0E3F845C-C37F-4120-BA07-8067D10CD886Q36728665-7AFB37E5-75C5-429A-9B72-32D9130D59F9Q36811537-F5F580EC-AD7F-4877-9F64-6D913FF0F5E7Q37101714-BE07B9E7-B156-4EFA-B5A6-363EB79489B8Q37248049-CB644B60-0653-40FE-BDF1-82BF6120965DQ37326899-E36A0055-4218-4E8B-8217-CE203D5525DFQ37965663-A9CCC278-4201-4246-8099-B878F01EA036Q38081716-9BFC659E-0A76-4EED-B71A-3B3CC7E00E21Q38093852-DA42E524-DC4F-4974-9BE8-3F7AB0FF5349Q38164684-19539AA3-4A6E-4077-830D-2CCB4FB9F528Q38770432-72BED242-8FD4-4E77-A200-A1BF1B308A86Q40294759-2AF1E59E-8430-44D4-98D6-169B3B6D32D5Q40468239-085DAB94-652D-4648-BCA6-F21393CC3CC3Q43714733-4038D119-592C-4652-BFE1-A563DF9C147BQ43836240-9C84FBD2-EBD3-4207-B64A-E6E32A1355E9Q44487385-105F147D-89FE-4157-AFF5-0F52D9997D79Q45281477-162E51DF-AC6F-43D5-99C3-B15CA6744E85Q46565998-BDA7D43C-53EF-4905-A587-6D639793068FQ47130381-53FF84A6-0215-4187-BA54-59C9AD6DD22EQ56113559-05EAB7DB-3B7B-4304-BE95-7964104C4698
P2860
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
@ast
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
@en
Torsades de pointes associated with high dose levomethadyl acetate
@nl
type
label
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
@ast
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
@en
Torsades de pointes associated with high dose levomethadyl acetate
@nl
prefLabel
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
@ast
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
@en
Torsades de pointes associated with high dose levomethadyl acetate
@nl
P2093
P2860
P356
P1476
Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).
@en
P2093
P2860
P356
10.1300/J069V20N04_02
P577
2001-01-01T00:00:00Z